SG11201803643TA - Virulence attenuated bacteria for treatment of malignant solid tumors - Google Patents

Virulence attenuated bacteria for treatment of malignant solid tumors

Info

Publication number
SG11201803643TA
SG11201803643TA SG11201803643TA SG11201803643TA SG11201803643TA SG 11201803643T A SG11201803643T A SG 11201803643TA SG 11201803643T A SG11201803643T A SG 11201803643TA SG 11201803643T A SG11201803643T A SG 11201803643TA SG 11201803643T A SG11201803643T A SG 11201803643TA
Authority
SG
Singapore
Prior art keywords
international
basel
rule
malignant solid
virulence attenuated
Prior art date
Application number
SG11201803643TA
Other languages
English (en)
Inventor
Simon Ittig
Marlise Amstutz
Christoph Kasper
Guy R Cornelis
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of SG11201803643TA publication Critical patent/SG11201803643TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201803643TA 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors SG11201803643TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15195490 2015-11-19
PCT/EP2016/078084 WO2017085233A1 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors

Publications (1)

Publication Number Publication Date
SG11201803643TA true SG11201803643TA (en) 2018-06-28

Family

ID=54697464

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803643TA SG11201803643TA (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors

Country Status (24)

Country Link
US (1) US11166987B2 (sr)
EP (2) EP3903813A1 (sr)
JP (1) JP7060503B2 (sr)
KR (1) KR20180081583A (sr)
CN (1) CN108472348B (sr)
AU (1) AU2016358257B2 (sr)
BR (2) BR112018009753B1 (sr)
CA (1) CA3003563A1 (sr)
CY (1) CY1124564T1 (sr)
DK (1) DK3377094T3 (sr)
EA (1) EA201890868A1 (sr)
ES (1) ES2880431T3 (sr)
HK (1) HK1256137A1 (sr)
HR (1) HRP20211191T1 (sr)
HU (1) HUE055132T2 (sr)
IL (1) IL259052B2 (sr)
LT (1) LT3377094T (sr)
PL (1) PL3377094T3 (sr)
PT (1) PT3377094T (sr)
RS (1) RS62152B1 (sr)
SG (1) SG11201803643TA (sr)
SI (1) SI3377094T1 (sr)
WO (1) WO2017085233A1 (sr)
ZA (1) ZA201803902B (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115960919A (zh) 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
HUE051184T2 (hu) 2015-11-19 2021-03-01 Univ Basel Baktériumalapú fehérjeszállítás
PT3559022T (pt) 2016-12-20 2021-08-19 Univ Basel Distribuição de proteínas baseada em bactérias com virulência atenuada
KR102110993B1 (ko) * 2018-12-20 2020-05-14 한국생명공학연구원 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물
KR20230098197A (ko) * 2020-10-27 2023-07-03 티3 파마슈티컬스 아게 세균 기반한 단백질 전달
CN114712496B (zh) * 2022-04-29 2023-10-13 中山大学·深圳 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
WO2000002996A2 (en) 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
WO2002026819A2 (en) 2000-09-26 2002-04-04 Roger Williams Hospital Recombinant bcg vaccines for the prevention and treatment of cancer
WO2002077249A2 (en) * 2001-03-26 2002-10-03 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
EP1565185A4 (en) 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
JP2009510169A (ja) 2005-10-04 2009-03-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 細菌抗原送達系を用いた免疫応答を刺激するための方法
WO2008019183A2 (en) 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
AU2009226972B2 (en) 2008-03-17 2014-05-29 Gerhard Heusipp YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
US10709784B2 (en) 2011-06-08 2020-07-14 Chelation Partners Incorporated Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism
US9127284B2 (en) * 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
CN113563478A (zh) 2013-09-24 2021-10-29 梅迪塞纳医疗股份有限公司 白介素-4受体结合融合蛋白及其应用
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
CN115960919A (zh) 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
HUE051184T2 (hu) 2015-11-19 2021-03-01 Univ Basel Baktériumalapú fehérjeszállítás
PT3559022T (pt) 2016-12-20 2021-08-19 Univ Basel Distribuição de proteínas baseada em bactérias com virulência atenuada

Also Published As

Publication number Publication date
RS62152B1 (sr) 2021-08-31
AU2016358257A1 (en) 2018-05-10
BR112018009753A2 (pt) 2018-11-13
ES2880431T3 (es) 2021-11-24
EP3377094A1 (en) 2018-09-26
CN108472348A (zh) 2018-08-31
LT3377094T (lt) 2021-08-10
HK1256137A1 (zh) 2019-09-13
PL3377094T3 (pl) 2021-12-13
EA201890868A1 (ru) 2018-12-28
JP2019500026A (ja) 2019-01-10
PT3377094T (pt) 2021-07-08
EP3903813A1 (en) 2021-11-03
SI3377094T1 (sl) 2021-09-30
CA3003563A1 (en) 2017-05-26
IL259052B2 (en) 2024-03-01
JP7060503B2 (ja) 2022-04-26
HRP20211191T1 (hr) 2021-10-29
EP3377094B1 (en) 2021-04-28
IL259052A (en) 2018-07-31
BR112018009753B1 (pt) 2024-02-20
WO2017085233A1 (en) 2017-05-26
US20190015497A1 (en) 2019-01-17
KR20180081583A (ko) 2018-07-16
BR112018009753A8 (pt) 2019-02-26
HUE055132T2 (hu) 2021-11-29
BR122023024697A2 (pt) 2023-12-26
DK3377094T3 (da) 2021-08-02
AU2016358257B2 (en) 2023-08-17
CN108472348B (zh) 2022-12-27
US11166987B2 (en) 2021-11-09
IL259052B1 (en) 2023-11-01
ZA201803902B (en) 2019-03-27
CY1124564T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201803643TA (en) Virulence attenuated bacteria for treatment of malignant solid tumors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811432WA (en) Rna for cancer therapy
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201803642WA (en) Bacteria-based protein delivery
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same